Siemens Fonds Invest GmbH Sells 22,764 Shares of Amgen Inc. (NASDAQ:AMGN)

Siemens Fonds Invest GmbH lessened its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 87.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,135 shares of the medical research company’s stock after selling 22,764 shares during the quarter. Siemens Fonds Invest GmbH’s holdings in Amgen were worth $817,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in AMGN. Capital World Investors increased its position in shares of Amgen by 1,292.0% during the fourth quarter. Capital World Investors now owns 6,495,710 shares of the medical research company’s stock worth $1,693,042,000 after purchasing an additional 6,029,058 shares in the last quarter. Norges Bank purchased a new stake in Amgen in the fourth quarter valued at about $1,541,991,000. Capital International Investors raised its stake in Amgen by 40.1% in the fourth quarter. Capital International Investors now owns 12,212,065 shares of the medical research company’s stock valued at $3,182,843,000 after buying an additional 3,495,503 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in Amgen by 25.4% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 13,205,604 shares of the medical research company’s stock worth $3,441,909,000 after acquiring an additional 2,672,975 shares in the last quarter. Finally, Raymond James Financial Inc. purchased a new stake in shares of Amgen during the fourth quarter worth about $401,913,000. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Amgen Stock Up 0.3%

AMGN stock opened at $272.41 on Friday. Amgen Inc. has a one year low of $253.30 and a one year high of $346.85. The company has a debt-to-equity ratio of 9.62, a quick ratio of 0.95 and a current ratio of 1.26. The firm’s fifty day moving average is $291.00 and its 200 day moving average is $288.09. The firm has a market cap of $146.48 billion, a PE ratio of 36.08, a P/E/G ratio of 2.63 and a beta of 0.51.

Amgen (NASDAQ:AMGN) last posted its earnings results on Thursday, May 1st. The medical research company reported $4.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.18 by $0.72. Amgen had a net margin of 12.24% and a return on equity of 176.32%. The business had revenue of $8.15 billion for the quarter, compared to analyst estimates of $8.05 billion. During the same period in the prior year, the company posted $3.96 EPS. The company’s revenue for the quarter was up 9.4% on a year-over-year basis. On average, research analysts forecast that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Friday, May 16th will be given a $2.38 dividend. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.49%. The ex-dividend date of this dividend is Friday, May 16th. Amgen’s dividend payout ratio (DPR) is presently 86.86%.

Insider Transactions at Amgen

In other news, EVP David M. Reese sold 8,711 shares of the business’s stock in a transaction dated Wednesday, February 19th. The shares were sold at an average price of $293.22, for a total transaction of $2,554,239.42. Following the completion of the sale, the executive vice president now owns 62,147 shares of the company’s stock, valued at $18,222,743.34. The trade was a 12.29% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 0.76% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on AMGN shares. Bank of America boosted their target price on shares of Amgen from $275.00 to $294.00 and gave the stock an “underperform” rating in a research report on Wednesday, March 5th. Johnson Rice set a $294.00 price objective on shares of Amgen in a research note on Wednesday, March 5th. Cantor Fitzgerald started coverage on shares of Amgen in a report on Tuesday, April 22nd. They set a “neutral” rating and a $305.00 price objective on the stock. UBS Group reissued a “neutral” rating and issued a $315.00 target price (down from $319.00) on shares of Amgen in a research report on Friday, May 2nd. Finally, Piper Sandler lowered their price target on Amgen from $329.00 to $328.00 and set an “overweight” rating for the company in a research report on Friday. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating, nine have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $310.18.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.